JP5149897B2 - 抗血栓作用を有するイミノイミダゾピリジン誘導体 - Google Patents

抗血栓作用を有するイミノイミダゾピリジン誘導体 Download PDF

Info

Publication number
JP5149897B2
JP5149897B2 JP2009522134A JP2009522134A JP5149897B2 JP 5149897 B2 JP5149897 B2 JP 5149897B2 JP 2009522134 A JP2009522134 A JP 2009522134A JP 2009522134 A JP2009522134 A JP 2009522134A JP 5149897 B2 JP5149897 B2 JP 5149897B2
Authority
JP
Japan
Prior art keywords
alkylene
alkyl
methoxy
het
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009522134A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009545542A (ja
JP2009545542A5 (cg-RX-API-DMAC7.html
Inventor
ウーヴェ・ハイネルト
アルミン・ホーフマイスター
イェルク・ツェヒ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2009545542A publication Critical patent/JP2009545542A/ja
Publication of JP2009545542A5 publication Critical patent/JP2009545542A5/ja
Application granted granted Critical
Publication of JP5149897B2 publication Critical patent/JP5149897B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009522134A 2006-08-02 2007-07-18 抗血栓作用を有するイミノイミダゾピリジン誘導体 Expired - Fee Related JP5149897B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006036023.0 2006-08-02
DE102006036023A DE102006036023A1 (de) 2006-08-02 2006-08-02 Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
PCT/EP2007/006360 WO2008014888A2 (de) 2006-08-02 2007-07-18 Imino-imidazo-pyridinderivate mit antithrombotischer aktivität

Publications (3)

Publication Number Publication Date
JP2009545542A JP2009545542A (ja) 2009-12-24
JP2009545542A5 JP2009545542A5 (cg-RX-API-DMAC7.html) 2010-09-02
JP5149897B2 true JP5149897B2 (ja) 2013-02-20

Family

ID=38884850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009522134A Expired - Fee Related JP5149897B2 (ja) 2006-08-02 2007-07-18 抗血栓作用を有するイミノイミダゾピリジン誘導体

Country Status (23)

Country Link
US (1) US7863269B2 (cg-RX-API-DMAC7.html)
EP (1) EP2054412B1 (cg-RX-API-DMAC7.html)
JP (1) JP5149897B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090129981A (cg-RX-API-DMAC7.html)
CN (1) CN101495478B (cg-RX-API-DMAC7.html)
AR (1) AR062158A1 (cg-RX-API-DMAC7.html)
AT (1) ATE450537T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007280780B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0714599A2 (cg-RX-API-DMAC7.html)
CA (1) CA2663332C (cg-RX-API-DMAC7.html)
CL (1) CL2007002240A1 (cg-RX-API-DMAC7.html)
DE (2) DE102006036023A1 (cg-RX-API-DMAC7.html)
DK (1) DK2054412T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2007000120A (cg-RX-API-DMAC7.html)
ES (1) ES2336044T3 (cg-RX-API-DMAC7.html)
IL (1) IL196789A (cg-RX-API-DMAC7.html)
MX (1) MX2009000408A (cg-RX-API-DMAC7.html)
MY (1) MY148611A (cg-RX-API-DMAC7.html)
NO (1) NO20090741L (cg-RX-API-DMAC7.html)
PE (1) PE20080687A1 (cg-RX-API-DMAC7.html)
PT (1) PT2054412E (cg-RX-API-DMAC7.html)
TW (1) TWI400240B (cg-RX-API-DMAC7.html)
WO (1) WO2008014888A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY152040A (en) * 2008-02-05 2014-08-15 Sanofi Aventis Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
KR20150122786A (ko) 2013-03-15 2015-11-02 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) 암 전이의 진단, 예후 및 치료를 위한 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5124517B1 (cg-RX-API-DMAC7.html) 1971-03-15 1976-07-24
DE2221796A1 (de) 1972-05-04 1973-11-15 Kraemer Kg Wilhelm Batteriebehaelter fuer stabbatterien
JPS60161986A (ja) * 1983-12-24 1985-08-23 Nippon Soda Co Ltd イミダゾ(1,5−a)ピリジン−3−オン誘導体及びその製造方法
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
US7488742B2 (en) 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
RU2270192C2 (ru) * 2001-04-19 2006-02-20 Эйсай Ко., Лтд. Производные 2-иминопирролидина
EP1982984B1 (en) 2002-04-16 2013-02-13 Merck Sharp & Dohme Corp. Manufacture of tricyclic thrombin receptor antagonists and pharmaceutical compositions comprising them
EP1602646A4 (en) 2003-02-19 2010-07-28 Eisai R&D Man Co Ltd PROCESS FOR PREPARING CYCLIC BENZAMIDINE DERIVATIVES
DE10353205A1 (de) 2003-11-13 2005-06-16 Aventis Pharma Deutschland Gmbh Ortho-substituierte Pentafluorsulfuranyl-Benzole, Verfahren zu ihrer Herstellung sowie ihre Verwendung als wertvolle Synthese-Zwischenstufen
US7317124B2 (en) 2003-11-13 2008-01-08 Sanofi-Aventis Deutschland Gmbh Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates

Also Published As

Publication number Publication date
KR20090129981A (ko) 2009-12-17
US7863269B2 (en) 2011-01-04
PT2054412E (pt) 2010-02-04
CN101495478A (zh) 2009-07-29
DK2054412T3 (da) 2010-04-19
NO20090741L (no) 2009-02-16
WO2008014888A3 (de) 2008-06-12
DE102006036023A1 (de) 2008-02-07
TWI400240B (zh) 2013-07-01
US20090192150A1 (en) 2009-07-30
ES2336044T3 (es) 2010-04-07
JP2009545542A (ja) 2009-12-24
DE502007002219D1 (de) 2010-01-14
TW200821308A (en) 2008-05-16
EP2054412A2 (de) 2009-05-06
MY148611A (en) 2013-05-15
AR062158A1 (es) 2008-10-22
MX2009000408A (es) 2009-01-27
AU2007280780A1 (en) 2008-02-07
HK1135694A1 (en) 2010-06-11
IL196789A0 (en) 2009-11-18
IL196789A (en) 2012-07-31
PE20080687A1 (es) 2008-07-24
CA2663332A1 (en) 2008-02-07
CA2663332C (en) 2015-06-02
CN101495478B (zh) 2013-03-27
AU2007280780B2 (en) 2012-03-29
BRPI0714599A2 (pt) 2013-04-09
WO2008014888A2 (de) 2008-02-07
ATE450537T1 (de) 2009-12-15
CL2007002240A1 (es) 2008-02-08
DOP2007000120A (es) 2008-02-29
EP2054412B1 (de) 2009-12-02

Similar Documents

Publication Publication Date Title
US8466169B2 (en) SF5 derivatives as PAR1 inhibitors, production thereof, and use as medicaments
US8044208B2 (en) Imidazole derivatives as inhibitors of TAFIa
JP5249226B2 (ja) 凝固第IXa因子インヒビターとしての使用のためのイソセリン誘導体
JP5570434B2 (ja) Par1阻害剤としてのイミダゾピリダジン類、その製造、及び薬剤としての使用
DK2104497T3 (en) SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA
JP5249225B2 (ja) 凝固第IXa因子インヒビターとしての使用のための酒石酸誘導体
JP2009545542A (ja) 抗血栓作用を有するイミノイミダゾピリジン誘導体
JP4861179B2 (ja) マトリックスメタロプロテイナーゼの阻害剤として使用される二環式イミノ酸誘導体
HK1135694B (en) Imino-imidazo-pyridine derivatives having antithrombotic activity
HK1148956B (en) Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121012

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121130

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151207

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees